Search results
Author(s):
Fumiyuki Otsuka
,
Masataka Nakano
,
Saami K Yazdani
,
et al
Added:
3 years ago
Percutaneous coronary interventions (PCI) involving stenting are the most widely performed procedures for the treatment of symptomatic coronary disease.1 Although first-generation sirolimus-eluting stents (SES; Cypher™, Cordis Corp., Miami Lakes, FL) and paclitaxel-eluting stents (PES; Taxus™, Boston Scientific, Natick, MA) have radically reduced restenosis,2,3 complications of late (LST) and…
View more
Author(s):
Meril Life Sciences
Added:
3 years ago
The first-generation drug-eluting stents (DES) initially demonstrated good promise in terms of reducing the degree of restenosis. They succeeded in arresting the neo-intimal proliferation, which was the bane of coronary stents.1 Over a period of time, however, the polymeric degradation by-products failed to bring about an essential component of the healing process: endothelialisation. Failure of…
View more
Advances in New Stent Designs without a Permanent Polymer May Solve Polymer-related Complications
Author(s):
Chourmouzios A Arampatzi
,
Raul Moreno
,
Giuseppe Sangiorgi
Added:
3 years ago
Article
Author(s):
Adnan Kastrati
Added:
3 years ago
Compared with conventional bare-metal stents (BMS), the introduction of drug-eluting stents (DES) has resulted in a substantial reduction in the incidence of in-stent restenosis.1 DES systems eluting either sirolimus2 or paclitaxel3 from a polymer stent coating have been shown in randomised trials to effectively inhibit the process of neointimal proliferation, resulting in restenosis reduction.
…
View more
Author(s):
Walter Desmet
Added:
3 years ago
Since its introduction in 1977, the long-term benefits of percutaneous coronary intervention have been limited by the phenomenon of restenosis, i.e. the recurrence of significant stenosis at the site of intervention. While in restenosis after plain balloon angioplasty roughly two-thirds of the late lumen loss is due to negative vessel wall remodelling, the late lumen loss after stent implantation…
View more
Author(s):
Roberto Diletti
,
Nicolas M Van Mieghem
Added:
3 years ago
Since Andreas Gruentzig presented his pioneering work in 1977, 'three revolutions' in percutaneous coronary interventions (PCI) have characterised the field of interventional cardiology. Plain old balloon angioplasty (POBA) was refined by the introduction of bare metal stenting (BMS) (second revolution) to address the issue of acute vessel recoil and unacceptably high rates of restenosis. Drug…
View more
Author(s):
Gregg Stone
Added:
3 years ago
Drug-eluting stents (DES) are the standard percutaneous treatment strategy in patients with coronary artery disease (CAD). Their use has further reduced the incidence of restenosis and repeatrevascularisation in single vessel de novo disease. These stents have bioactive coatings that, through a complex mechanism, allow the release of various antiinflammatory and anti-proliferative drugs at high…
View more
Bionert Stent Angiographic Study
Author(s):
Eulogio García Fernandez
,
Didier Carrie
,
Amadeu Betriu
,
et al
Added:
3 years ago
Article
Author(s):
Albert Schömig
,
Adnan Kastrati
Added:
3 years ago
Drug-eluting stents (DES) have largely resolved the problem of restenosis, which is the major limitation of plain balloon angioplasty and bare-metal stenting.1 While several DES platforms have been evaluated in the setting of randomised studies and used in clinical practice, most of the accumulated evidence is related to sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES).2 These…
View more
Author(s):
Daniel Tze Yee Ang
,
Colin Berry
Added:
2 years ago